Fagron is currently leading in pharmaceutical compounding and is active in 35 countries, with products and innovations sold to over 200,000 customers in over 60 countries around the world. The company intends to achieve growth by growing organically as well as by making selective acquisitions that complement and expand the existing strengths.
Cyborg Score Rationale
Fagron demonstrates solid fundamentals with ~$1B revenue, strong market position in pharmaceutical compounding, and global distribution across 60+ countries. Recent acquisitions (Purifarma) and facility expansions show execution on growth strategy.
Top Insights
North America is majority revenue driver with strong Compounding Services and Brands & Essentials segments showing operational excellence
Recently signed three acquisitions including Purifarma in Brazil to strengthen regional presence and drive procurement synergies
Global expansion underway with ~70 offices and compounding facilities enabling organic growth across EMEA, North America, and Latin America
Confirmed 2025 full-year revenue guidance of $930-950M with improved profitability and CapEx discipline at 3.5% of revenues
Named Competitors
Compounding Services — Pharmaceutical compounding and custom formulation services
Pharmaceutical Manufacturing — Pharmaceutical manufacturing and compounding solutions
Manufacturing Services — Large-scale pharmaceutical manufacturing and distribution
Recent Developments
(November 2025) Confirmed full-year revenue guidance of €930-950M with improved profitability
(November 2025) Announced three acquisitions including Purifarma in Brazil to expand regional presence
(Q3 2025) Reported strong quarterly results with improved performance in EMEA and accelerated growth in Latin America
Open the full interactive Fagron NV report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.